ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)
$12.6 -0.4 (-3.0769%)
Analysed ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) News Sources
Enanta Pharmaceuticals Insider Ups Holding During Year
01-01-2026
yahoo.com
JPM26: Enanta outlines strategy to lead in RSV therapeutics
15-01-2026
pharmaceutical-technology.com
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
09-02-2026
yahoo.com
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
09-02-2026
yahoo.com
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
12-02-2026
yahoo.com
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
15-03-2026
marketbeat.com
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
07-05-2026
yahoo.com
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
07-05-2026
yahoo.com
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
11-05-2026
yahoo.com
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
24-06-2026
yahoo.com
What is the current price of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)?
The current price of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) is $12.6.
ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) since the previous trading day is $-0.4.
ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) since the previous trading day is -3.0769%.
What is the most recent average sentiment score for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)?
The most recent average sentiment score for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) is 57 out of 100.
What is the most recent average sentiment for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)?
The most recent sentiment for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) is .
SEC-8K** Filing Available For ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.